Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat

Pharmacology Biochemistry and Behavior

Volumn 110, Issue , 2013, Pages 265-271

  Hansen, Henrik H ^a   Jensen, Majbrit M ^b   Overgaard, Agnete ^b   Weikop, Pia ^c   Mikkelsen, Jens D ^b  

^a NEUROSEARCH A S   (Denmark)

^b University of Copenhagen   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

Dopamine; Obesity; Prefrontal cortex; Striatum; Tesofensine; Weight loss

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; TESOFENSINE;

ACUTE DRUG ADMINISTRATION; ANIMAL MODEL; ANIMAL TISSUE; APPETITE; ARTICLE; CONTROLLED STUDY; DIET; DIETARY INTAKE; DOPAMINERGIC ACTIVITY; FOREBRAIN; NONHUMAN; NUCLEUS ACCUMBENS; OBESITY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; SYSTEMATIC REVIEW; WEIGHT REDUCTION;

RATTUS;

DOPAMINE; OBESITY; PREFRONTAL CORTEX; STRIATUM; TESOFENSINE; WEIGHT LOSS;

ANIMALS; APPETITE; APPETITE DEPRESSANTS; BICYCLO COMPOUNDS, HETEROCYCLIC; DIET; DOPAMINE; IN SITU HYBRIDIZATION; MALE; OBESITY; PROSENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; WEIGHT LOSS;

EID: 84886914486     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.07.018     Document Type: Article

References (42)

1. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372: 1906-13.
2. Axel AMD, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 2010;35: 1464-76.
3. Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 2000;71: 68-78. (Pubitemid 30045337)
4. Brown HD, McCutcheon JE, Cone JJ, RagozzinoME, RoitmanMF. Primary food reward and reward-predictive stimuli evoke different patterns of phasic dopamine signaling throughout the striatum. Eur J Neurosci 2011;34: 1997-2006.
5. Chen JF, Qin ZH, Szele F, Bai G, Weiss B. Neuronal localization and modulation of the D2 dopamine receptor mRNA in brain of normal mice and mice lesioned with 6-hydroxydopamine. Neuropharmacology 1991;30: 927-41.
6. Davis JF, Tracy AL, Schurdak JD, Tschöp MH, Lipton JW, Clegg DJ, et al. Exposure to elevated levels of dietary fat attenuates psychostimulant reward andmesolimbic dopamine turnover in the rat. Behav Neurosci 2008;122: 1257-63.
7. Davis LM, Michaelides M, Cheskin LJ, Moran TH, Aja S, Watkins PA, et al. Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity. Neuroendocrinology 2009;89: 152-62.
8. Geiger BM, Behr GG, Frank LE, Caldera-Siu AD, Beinfeld MC, Kokkotou EG, et al. Evidence for defective mesolimbic dopamine exocytosis in obesity-prone rats. FASEB J 2008;22: 2740-6.
9. Geiger BM, Haburcak M, Avena NM, Moyer MC, Hoebel BG, Pothos EN. Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. Neuroscience 2009;159: 1193-9.
10. Gilbert JA, Gasteyger C, Raben A,Meier DH, Astrup A, Sjödin A. The effect of tesofensine on appetite sensations. Obesity (Silver Spring) 2012;20: 553-61.
11. Hansen HH, Hansen G, Tang-ChristensenM, Larsen PJ, Axel AMD, Raben A, et al. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol 2010;636: 88-95.
12. Huang XF, Zavitsanou K, Huang X, Yu Y,Wang H, Chen F, et al. Dopamine transporter and D2 receptor binding densities in mice prone or resistant to chronic high fat diet-induced obesity. Behav Brain Res 2006;175: 415-9. (Pubitemid 44750233)
13. Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci 2010;13: 635-41.
14. Lehr T, Staab A, Tillmann C, Nielsen EØ, Trommeshauser D, Schaefer HG, et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol 2008;153: 164-74.
15. MazeiMS, Pluto CP, Kirkbride B, Pehek EA. Effects of catecholamine uptake blockers in the caudate-putamen and subregions of themedial prefrontal cortex of the rat. Brain Res 2002;936: 58-67. (Pubitemid 34461933)
16. Meguid MM, Fetissov SO, Varma M, Sato T, Zhang L, Laviano A, et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000;16: 843-57.
17. Metaxas A, Bailey A, Barbano MF, Galeote L, Maldonado R, Kitchen I. Differential regionspecific regulationof α4β2* nAChRs by self-administered and non-contingent nicotine in C57BL/6 J mice. Addict Biol 2010;15: 464-79.
18. Mikkelsen JD,Woldbye D, Kragh J, Larsen PJ, Bolwig TG. Electroconvulsive shocks increase the expression of neuropeptide Y (NPY)mRNA in the piriform cortex and the dentate gyrus. Brain Res Mol Brain Res 1994;23: 317-22. (Pubitemid 24158084)
19. Paxinos G, Watson W. The rat brain in stereotaxic coordinates. London, UK: London: Academic Press Ltd.; 1986.
20. Pothos EN, Sulzer D, Hoebel BG. Plasticity of quantal size in ventral midbrain dopamine neurons: possible implications for the neurochemistry of feeding and reward. Appetite 1998;31:405. (Pubitemid 29020924)
21. Roitman MF, van Dijk G, Thiele TE, Bernstein IL. Dopamine mediation of the feeding response to violations of spatial and temporal expectancies. Behav Brain Res 2001;122: 193-9. (Pubitemid 32396774)
22. RoitmanMF, Wheeler RA, Wightman RM, Carelli RM. Real-time chemical responses in the nucleus accumbens differentiate rewarding and aversive stimuli. Nat Neurosci 2008;11: 1376-7.
23. Rolls ET. The functions of the orbitofrontal cortex. Brain Cogn 2004;55: 11-29. (Pubitemid 38591427)
24. Rothemund Y, Preuschhof C, Bohner G, Bauknecht HC, Klingebiel R, Flor H, et al. Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals. Neuroimage 2007;37: 410-21. (Pubitemid 47444263)
25. Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther 2010;88: 69-78.
26. Sjödin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JKS, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight andmoderately obese men. Int J Obes (Lond) 2010;34: 1634-43.
27. Small DM, Jones-Gotman M, Dagher A. Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. Neuroimage 2003;19: 1709-15. (Pubitemid 37025866)
28. South T, Huang X. High-fat diet exposure increases dopamine D2 receptor and decreases dopamine transporter receptor binding density in the nucleus accumbens and caudate putamen of mice. Neurochem Res 2008;33: 598-605. (Pubitemid 351230463)
29. Stice E, Spoor S, Bohon C, Small DM. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 2008;322: 449-52.
30. Stice E, Spoor S, Ng J, Zald DH. Relation of obesity to consummatory and anticipatory food reward. Physiol Behav 2009;97: 551-60.
31. Stice E, Yokum S, Blum K, Bohon C. Weight gain is associated with reduced striatal response to palatable food. J Neurosci 2010;30: 13105-9.
32. Terry P, Gilbert DB, Cooper SJ. Dopamine receptor subtype agonists and feeding behavior. Obes Res 1995;3(Suppl. 4):515S-23S.
33. van de Giessen E, de Bruin K, la Fleur SE, van den Brink W, Booij J. Triple monoamine inhibitor tesofensine decreases food intake, bodyweight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. Eur Neuropsychopharmacol 2012;22: 290-9.
34. Volkow ND,Wise RA. How can drug addiction help us understand obesity? Nat Neurosci 2005;8: 555-60. (Pubitemid 40594193)
35. Volkow ND,Wang GJ, Telang F, Fowler JS, Goldstein RZ, Alia-Klein N, et al. Inverse association between BMI and prefrontalmetabolic activity in healthy adults. Obesity (Silver Spring) 2009;17: 60-5. (Pubitemid 50310542)
36. Volkow ND,Wang GJ, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn Sci 2011;15: 37-46.
37. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, et al. Brain dopamine and obesity. Lancet 2001;357: 354-7. (Pubitemid 32128542)
38. Wang GJ, Volkow ND, Telang F, Jayne M, Ma J, Rao M, et al. Exposure to appetitive food stimuli markedly activates the human brain. Neuroimage 2004;21: 1790-7. (Pubitemid 38446599)
39. Weikop P, Kehr J, Scheel-Krüger J. The role of alpha1- and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. J Psychopharmacol 2004;18: 395-403. (Pubitemid 39382568)
40. Weiner DM, Levey AI, Sunahara RK, Niznik HB, O'Dowd BF, Seeman P, et al. D1 and D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci U S A 1991;88: 1859-63. (Pubitemid 21916326)
41. Wellman PJ. Norepinephrine and the control of food intake. Nutrition 2000;16: 837-42.
42. Wilmot CA, Sullivan AC, Levin BE. Effects of diet and obesity on brain alpha 1- and alpha 2-noradrenergic receptors in the rat. Brain Res 1988;453: 157-66.